A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Unless the context otherwise requires, for purposes of this section, the terms “we,” “us,” “our,” “our Company,” “the Company” or “Senti” refer to Senti Biosciences, Inc. and its subsidiaries. We are a clinical-stage biotechnology company developing next-generation cell and gene therapies engineered with our gene circuit platform technologies for patients living with incurable diseases. Our mission is to create a new generation of smarter medicines that outsmart complex diseases using novel and unprecedented approaches. To accomplish this mission, we have built a synthetic biology platform that we believe may enable us to program next-generation cell and gene therapies with gene circuits. These gene circuits, which we created from novel and proprietary combinations of DNA sequences, are designed to reprogram cells with biological logic to sense inputs, compute decisions and respond to their respective cellular environments.
| Segment | 2023 | % of Total |
|---|---|---|
Reportable Segment | $2M | 100% |
| Metric | TTM | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | - | - | - |
| Net Income | -48M | -53M | -71M | -58M | -55M |
| EPS | $-2.87 | $-12.03 | $-16.01 | $-22.30 | $-190.00 |
| Free Cash Flow | 0 | -41M | -64M | -76M | -40M |
| ROIC | -99.4% | -188.0% | -109.5% | -45.7% | -33.0% |
| Gross Margin | - | - | - | - | - |
| Debt/Equity | 0.00 | 1.84 | 0.79 | 0.42 | -0.33 |
| Dividends/Share | $0.00 | - | - | - | - |
| Operating Income | -66M | -61M | -93M | -62M | -40M |
| Operating Margin | 0.0% | - | - | - | - |
| ROE | -585.9% | -114.1% | -106.2% | -45.7% | - |
| Shares Outstanding | 26M | 26M | 26M | 3M | 4M |
| Metric | 2021 | 2022 | |||
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | N/A | N/A | N/A | 0 | 0 |
| Gross Margin | N/A | N/A | N/A | N/A | N/A |
| R&D | N/A | N/A | N/A | N/A | N/A |
| SG&A | N/A | N/A | N/A | N/A | N/A |
| EBIT | -40M | -62M | -93M | -61M | -66M |
| Op. Margin | N/A | N/A | N/A | N/A | 0.0% |
| Net Income | -55M | -58M | -71M | -53M | -48M |
| Net Margin | N/A | N/A | N/A | N/A | 0.0% |
| Non-Recurring | 22K | 0 | 26M | 313K | 313K |
| Returns on Capital | |||||
| ROIC | -33.0% | -45.7% | -109.5% | -188.0% | -99.4% |
| ROE | N/A | -45.7% | -106.2% | -114.1% | -585.9% |
| ROA | -57.2% | -32.2% | -59.5% | -48.6% | -90.3% |
| Cash Flow | |||||
| Op. Cash Flow | -35M | -35M | -52M | -41M | -50M |
| Free Cash Flow | -40M | -76M | -64M | -41M | 0 |
| Owner Earnings | -38M | -53M | -66M | -47M | -56M |
| CapEx | 5.5M | 41M | 12M | 26K | 0 |
| Maint. CapEx | 769K | 1.4M | 3.6M | 3.8M | 3.8M |
| Growth CapEx | 4.8M | 40M | 8.5M | 0 | 0 |
| D&A | 769K | 1.4M | 3.6M | 3.8M | 3.8M |
| CapEx/OCF | N/A | N/A | N/A | N/A | 0.0% |
| Capital Allocation | |||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | N/A | N/A | N/A | N/A | 0.0% |
| Stock-Based Comp | 2.3M | 16M | 9.7M | 1.8M | 1.8M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Balance Sheet | |||||
| Net Debt | N/A | N/A | N/A | N/A | -12M |
| Cash & Equiv. | N/A | N/A | N/A | N/A | 12M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A |
| Debt/Equity | -0.33 | 0.42 | 0.79 | 1.84 | 0.00 |
| Interest Coverage | -3676.9 | -36.5 | -32.4 | -64.4 | -64.4 |
| Equity | -111M | 127M | 67M | 26M | 8.1M |
| Total Assets | 97M | 181M | 119M | 98M | 53M |
| Total Liabilities | 36M | 54M | 53M | 47M | 45M |
| Intangibles | N/A | N/A | N/A | N/A | N/A |
| Retained Earnings | -115M | -173M | -244M | -297M | -297M |
| Working Capital | 46M | 85M | 59M | 46M | 46M |
| Current Assets | 60M | 103M | 71M | 59M | 59M |
| Current Liabilities | 15M | 18M | 13M | 13M | 13M |
| Per Share Data | |||||
| EPS | -190.00 | -22.30 | -16.01 | -12.03 | -2.87 |
| Owner EPS | -8.54 | -20.18 | -2.52 | -1.81 | -2.12 |
| Book Value | -25.23 | 48.75 | 2.57 | 0.99 | 0.31 |
| Cash Flow/Share | -7.84 | -13.37 | -2.01 | -1.59 | -1.66 |
| Dividends/Share | N/A | N/A | N/A | N/A | 0.00 |
| Shares Out. | 4.4M | 2.6M | 26.0M | 26.0M | 26.3M |
| Valuation | |||||
| P/E Ratio | N/A | N/A | N/A | N/A | -0.3 |
| P/FCF | N/A | N/A | N/A | N/A | N/A |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A |
| Price/Book | N/A | 0.3 | 2.3 | 4.0 | 3.0 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A |
| FCF Yield | -9.2% | -232.8% | -41.9% | -40.6% | N/A |
| Market Cap | 437M | 33M | 154M | 102M | 24M |
| Avg. Price | 99.25 | 56.39 | 9.06 | 3.39 | 0.93 |
| Year-End Price | 98.90 | 12.55 | 5.91 | 3.92 | 0.93 |
Senti Biosciences, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Senti Biosciences, Inc. (SNTI) has a 5-year average return on invested capital (ROIC) of -94.1%. This is below average and may indicate limited pricing power.
Senti Biosciences, Inc. (SNTI) has a market capitalization of $24M. It is classified as a small-cap stock.
Senti Biosciences, Inc. (SNTI) does not currently pay a regular dividend.
Senti Biosciences, Inc. (SNTI) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
Senti Biosciences, Inc. (SNTI) generated $-41 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Senti Biosciences, Inc. (SNTI) has a debt-to-equity ratio of 1.84. This indicates higher leverage, which may increase financial risk.
Senti Biosciences, Inc. (SNTI) reported earnings per share (EPS) of $-12.03 in its most recent fiscal year.
Senti Biosciences, Inc. (SNTI) has a return on equity (ROE) of -114.1%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 4 years of financial data for Senti Biosciences, Inc. (SNTI), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Senti Biosciences, Inc. (SNTI) has a book value per share of $0.99, based on its most recent annual SEC filing.